- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jennifer Malin Predicts Biosimilars Will Have Little Impact on Treatment Costs
The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.
The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.
She added that biosimilars are still expensive to produce and will therefore not have the same impact as generics do in relation to costs.
“The challenge is just that in the face of biosimilars, we also have newer molecules that are coming out that are more effective in some cases than the older versions that now have biosimilars available,” Dr Malin said.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
